🌟 A new era in Belgian healthcare 🌟 We are thrilled to announce the release of our strategic partner PwC's latest publication, "A New Era in Belgian Healthcare". This comprehensive whitepaper delves into the challenges and opportunities within Belgium's healthcare system, emphasizing the transition towards Value-Based Healthcare (VBHC). Key insights from the publication highlight the necessity for a fundamental transformation to ensure sustainable, high-quality care for future generations. By adopting VBHC, Belgium can enhance health outcomes, improve patient and provider experiences, and ensure equity in care delivery—all while optimizing costs. We invite you to explore the insights and actionable recommendations that aim to ensure a more resilient healthcare system in Belgium. 🔗 https://lnkd.in/gwm57XUs #HealthcareInnovation #VBHC #flandersbio #PwC #StrategicPartnership #BelgiumHealthcare
flanders.bio
Biotechnology Research
Ghent, Flemish Region 13,068 followers
the cluster organisation empowering a life sciences driven network economy.
About us
flanders.bio is the cluster organisation empowering a life sciences driven network economy. We help our members to create value by organising networking and training activities, supporting internationalisation, providing services and building expertise.
- Website
-
https://www.flanders.bio
External link for flanders.bio
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Ghent, Flemish Region
- Type
- Nonprofit
- Founded
- 2004
- Specialties
- Biotechnology, life sciences, Sector organisation, MedTech, Agrotechnology, biotech, healthcare, Cluster, and agtech
Locations
-
Primary
Technologiepark-Zwijnaarde 122
AA Tower
Ghent, Flemish Region 9052, BE
Employees at flanders.bio
-
Stefan Thys
Program Manager at argenx
-
Tom Aelbrecht
Head of Sustainable Business Strategy and Reporting (J&J Belgium)
-
Toon Musschoot
Head Investor Relations and Communications at Biotalys NV | Member of the Senior Leadership Team | Board Member at flanders.bio
-
Marieke Vermeersch
VP, Head of Corporate Communication at Galapagos
Updates
-
Allegro Biotech’s innovative injectable microparticle gel, #hydrocelin, has demonstrated favorable safety in two preclinical studies, paving the way for a breakthrough in #osteoarthritis treatment. By acting as tiny shock absorbers, hydrocelin offers immediate pain relief, helps restore mobility, and protects cartilage. “Effective disease-modifying treatments for osteoarthritis are urgently needed as our population ages, as well as for athletes who are looking for alternatives to invasive surgical procedures”, said Lucas D., CEO of Allegro. “We believe hydrocelin possesses the necessary attributes to offer osteoarthritis patients pain relief and potentially protect joints and restore mobility.” https://lnkd.in/e-AJSRdM
-
-
Exciting news for pet owners and veterinary professionals! 🐾 Benno Therapeutics has been awarded for “Most Innovative Animal Health Project” at the #BioFit conference in Lille. Their pioneering treatment for bladder cancer in #animals earned recognition from top #veterinary leaders, highlighting its potential to revolutionize care for #pets worldwide. Erwin Blomsma, CEO of Benno Therapeutics, shared: "We are proud that our young company, founded on February 29 this year, is already being recognized by the top players in the industry." https://lnkd.in/ehirKkMh
-
-
Wonderful times at the HealthTech Investor Summit! The conference kicked off with an engaging discussion titled ‘The Wolves of Med Street,’ highlighting the challenges and opportunities in the #healthtech investment landscape. The panelists emphasized the pressing need for liquidity in the market, as well as the potential for a more cohesive European market for health products by 2025. It's clear that while there are hurdles to overcome, such as the current investment climate, there is also a strong call for resilience and collaboration among private investors to drive innovation. The insights shared by the panelists reflect a commitment to supporting transformative healthtech solutions and navigating the evolving landscape together. It was an inspiring evening that reinforced the importance of #partnerships in propelling our industry forward! We at flanders.bio support these key take-aways and are convinced that resilience, collaboration & partnerships are the innovation drivers of tomorrow. MEDVIA #HTIS24
-
-
Researchers from VIB, Vrije Universiteit Brussel, Universiteit Gent, and etherna have developed a breakthrough mRNA immunotherapeutic platform using lipid-based nanoparticles (LNPs). This innovation stimulates the immune system to recognize and eliminate #cancer cells, and protects against #tumor rechallenge. 🧬 Dr. Stefaan De Koker, eTheRNA: “These results are a confirmation of the relevance of our immunotherapeutic platform for the development of future immunotherapies. Depending on the needs of different types of cancer, we can leverage our platform for various therapeutic mRNAs.” https://lnkd.in/eMzCEjwt
-
-
✨ Join us for the Flanders Life Sciences delegation to BioAsia 2025! Interested in learning more about the vibrant life sciences ecosystem in Bangalore and Hyderabad? This is your chance to connect with industry leaders, engage in B2B meetings, and explore innovative collaborations in #immunotherapy, #vaccines, and more. Discover how Flanders is positioned as an international R&D hub and build valuable synergies with key players in India’s thriving ecosystem. Yes, but ... you need more info first? We are organising an information session on 16th December from 10:00-11:00 CET. Participation is free but registration is necessary via this link 👉 https://lnkd.in/e36AAEiQ #bioasia #conference #biotech #lifesciences #collaboration
-
-
Galapagos shared promising data from the ongoing Phase 1/2 ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5101. The results show an encouraging efficacy and safety profile in patients with relapsed/refractory non-Hodgkin #lymphoma (R/R NHL). “CAR-T therapies are highly personalized treatments that currently undergo a time-intensive manufacturing process taking multiple weeks to months. For many patients with rapidly progressing #cancers, every day counts, and treatment delays can be detrimental,” said Dr Jeevan Shetty MD,FRCP,MBA, Head of Clinical Development Oncology at Galapagos. https://lnkd.in/e6mC83_G
-
-
Exciting news in Alzheimer's research. 🧠 Muna Therapeutics has partnered with GSK to explore innovative drug targets for Alzheimer's disease, using Muna’s groundbreaking MiND-MAP platform. This #collaboration leverages spatial transcriptomics and patient-derived data to uncover insights into brain resilience and identify new therapeutic opportunities. Rita Balice-Gordon, Ph.D., Muna’s Chief Executive Officer: "By combining GSK's commitment to breakthrough science with our MiND-MAP platform's ability to deliver novel insights into brain resilience, we aim to transform the landscape of drug discovery for neurodegenerative diseases and bring new hope to millions of patients worldwide." https://lnkd.in/exfPeiSJ
-
-
Vrije Universiteit Brussel and VIB join forces to launch the brand-new Bio Incubator Brussels (BIB) on the green VUB Main Campus in Etterbeek. This hub blends science, technology and entrepreneurship, to transform groundbreaking biotech advancements into new companies. The VIB Nanobody Core Facility was the first to move in. "With this new bio-incubator, we aim to facilitate the creation of start-ups in their early stages and strengthen the link between our lab and our spin-offs,” says Prof. Jan Steyaert, Scientific Director of the VIB-VUB Center for Structural Biology. https://lnkd.in/enBQMTie
-
-
We are happy to welcome OHMX.bio as a new member to the flanders.bio network! OHMX.bio operates as a premier Study Design Company. Their project management encompasses #sample preparation, advanced #data analysis, and sophisticated #reporting across transcriptomics, translatomics, proteomics, and (epi)genetics.
-